The biosimilar market has taken off in Europe and is poised to do so in the U.S. as approvals increase and payers begin to take notice. During this on-demand session, we explore this growth market with a look inside the expansion in Europe, strategies for tendering, and have a discussion of expected regulatory developments, pricing and competition, go-to-market strategies and innovation.

Hear from industry leaders from IQVIA and Fresenius Kabi as we share lessons learned in the European market as well as insight into the evolving U.S. market for biosimilars.